Injection of botulinum toxin before pneumatic dilatation in achalasia treatment: a randomized-controlled trial

Aliment Pharmacol Ther. 2006 Sep 15;24(6):983-9. doi: 10.1111/j.1365-2036.2006.03083.x.

Abstract

Background: Pneumatic dilatation is the first line therapy in achalasia, but half of patients relapse within 5 years of therapy and require further dilatations.

Aim: To assess whether botulinum toxin injection before pneumatic dilatation is superior to pneumatic dilatation alone in achalasia patients.

Methods: Newly diagnosed achalasia patients were randomly assigned to receive botulinum toxin 1 month before pneumatic dilatation (botulinum toxin-pneumatic dilatation group: 27 patients with median age of 38) or to undergo pneumatic dilatation alone (pneumatic dilatation group: 27 patients with median age of 30). Response to therapy was assessed by clinical and objective methods at various intervals.

Results: One-year remission rate of patients in botulinum toxin-pneumatic dilatation group was 77% compared with 62% in pneumatic dilatation group (P = 0.1). In pneumatic dilatation group, the oesophageal barium volume significantly (P < 0.001) decreased at 1 month, but this reduction did not persist over 1-year follow-up. Botulinum toxin-pneumatic dilatation group showed a significant (P < 0.001) reduction in barium volume at the various times intervals post-treatment. In the botulinum toxin-pneumatic dilatation group, 10/11 (91%) patients over 40 were in remission at 1 year, comparing with only five of nine (55%) cases in pneumatic dilatation group (P = 0.07).

Conclusion: Injection of botulinum toxin before pneumatic dilatation does not significantly enhance the efficacy of pneumatic dilatation.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age Factors
  • Anti-Dyskinesia Agents / administration & dosage*
  • Anti-Dyskinesia Agents / adverse effects
  • Barium / analysis
  • Botulinum Toxins / administration & dosage*
  • Botulinum Toxins / adverse effects
  • Catheterization / adverse effects
  • Catheterization / methods*
  • Esophageal Achalasia / physiopathology
  • Esophageal Achalasia / therapy*
  • Esophageal Sphincter, Lower / drug effects
  • Esophageal Sphincter, Lower / physiopathology
  • Esophagus / chemistry
  • Esophagus / physiopathology
  • Female
  • Humans
  • Injections
  • Male
  • Middle Aged
  • Prospective Studies
  • Recurrence
  • Treatment Outcome

Substances

  • Anti-Dyskinesia Agents
  • Barium
  • Botulinum Toxins